Recently, Makondi et al. demonstrated the enhancement of tumor responsiveness to irinotecan upon MAPK signal transduction pathway inhibition through the targeting of FGF2 in colorectal cancer [22]. This evidence concerns the gene FGF2 and neoplasm.